Revolution Medicines insider files Form 144 to sell 1,842 shares

Rhea-AI Filing Summary

Revolution Medicines (RVMD) filed a Form 144 notice for the proposed sale of 1,842 shares of common stock to be executed through ETRADE with an aggregate market value of $85,745.10. The filing shows the shares were acquired as restricted stock unit grants between 03/01/2022 and 03/01/2025 in five tranches totaling 1,842 shares, with the planned approximate sale date of 09/15/2025 on NASDAQ. The filer also reported two prior sales in the past three months by Jeff Cislini: 1,878 shares on 06/16/2025 for $74,800.74 and 1,912 shares on 06/20/2025 for $75,735.85. The filing lists total shares outstanding as 186,933,190, indicating the position is small relative to the company’s outstanding stock.

Positive

• Clear provenance of the shares is provided: all were acquired as restricted stock unit grants with dates and amounts itemized
• Broker and execution details are specified (ETRADE; NASDAQ), supporting orderly sale mechanics
• Prior sales disclosed for transparency: two transactions in June with amounts and gross proceeds listed

Negative

• Insider selling activity is present with two recent June sales plus the planned September sale, which may concern some investors despite small absolute size

Insights

Securities Analyst

TL;DR: Small, routine insider sale of RSU-derived shares; not material to cap structure but notable as insider liquidity.

The Form 144 documents a planned disposal of 1,842 shares derived from restricted stock unit grants awarded between 2022 and 2025, executed via a retail broker. At an aggregate value of $85.7k against 186.9 million shares outstanding, this sale is immaterial to the company’s market capitalization and likely reflects individual liquidity rather than a company-level signal. The disclosure of two recent June sales by the same named individual shows ongoing dispositions over the quarter. For investors, the transaction is transparent and consistent with Rule 144 mechanics; it does not provide substantive information about operating performance.

Compliance / Corporate Governance Expert

TL;DR: Filing appears procedural and compliant, documenting RSU origins and broker details; standard Rule 144 notice.

The submission includes the necessary elements for a Rule 144 notice: number of shares, broker identity, acquisition dates and nature (RSU grants), and recent sales history. The explicit listing of grant dates and that payment was for services supports the provenance of the shares. The presence of recent sales in June suggests the filer is actively liquidating portions of their holdings; however, the filing content shows disclosure steps being followed and does not indicate any apparent compliance exceptions in the provided fields.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	1842	85745.10	186933190	09/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/01/2022	Restricted stock unit grant	Issuer			190	03/01/2022	Services rendered
Common Stock	09/01/2022	Restricted stock unit grant	Issuer			193	09/01/2022	Services rendered
Common Stock	03/01/2023	Restricted stock unit grant	Issuer			497	03/01/2023	Services rendered
Common Stock	03/01/2024	Restricted stock unit grant	Issuer			470	03/01/2024	Services rendered
Common Stock	03/01/2025	Restricted stock unit grant	Issuer			492	03/01/2025	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jeff Cislini c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	06/16/2025	1878	74800.74
Jeff Cislini c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	06/20/2025	1912	75735.85

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Revolution Medicines (RVMD) shares are proposed for sale in this Form 144?

The notice shows a proposed sale of 1,842 shares of common stock.

What is the aggregate market value of the shares listed in the RVMD Form 144?

The aggregate market value reported is $85,745.10.

When is the approximate sale date and where will the RVMD shares be sold?

The approximate date of sale is 09/15/2025 and the securities exchange listed is NASDAQ.

How were the shares acquired that are being sold under this Form 144?

All 1,842 shares were acquired as restricted stock unit grants between 03/01/2022 and 03/01/2025 and were issued for services rendered.

Were there any recent sales by the same person prior to this Form 144 filing?

Yes. The filing reports sales by Jeff Cislini of 1,878 shares on 06/16/2025 for $74,800.74 and 1,912 shares on 06/20/2025 for $75,735.85.

Which broker is named for executing the planned sale?

The broker listed is ETRADE Financial Corporation (address shown in filing).